Fig. 1From: Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsMutational analysis results between MPR and non-MPR groups. a Landscape of frequent SNV and InDel on cancer driver genes. b Pathway enrichment analysis on mutated tumor suppressor genes. c Three HRD metrics including TAI, LST and HRD-LOH calculated on non-aneuploid samples. d HRDscore calculated on non-aneuploid samples. e Correlation between HRDscore and percentage of viable tumor cells in all non-aneuploid samplesBack to article page